|
Aug. 6, 2025
| This week’s commercialization news and insights for biopharma leaders
The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.
|
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to-consumer options.
|
The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for newly launched drugs.
|
GSK transformed drug development by investing in claims data early, challenging assumptions, and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI, and more in
|
Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed were “not a flash in the pan.”
|
A new pilot program from HHS will test alterations to the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.
|
From Our Library
Playbook
Custom content for Cardinal Health
|
View all resources
What We're Reading
Bloomberg
|
Financial Times
|
The Wall Street Journal
|
| 
